Keyphrases
Thrombotic Microangiopathy
100%
Atypical Hemolytic Uremic Syndrome (aHUS)
97%
Complement System
52%
Complement Activation
46%
Genetic Variants
40%
Complement Factors
35%
Complement Factor H
33%
C3 Glomerulopathy
28%
Kidney Transplantation
27%
Management Strategy
27%
Age-related Macular Degeneration
26%
Advanced Age-related Macular Degeneration
24%
Complement Receptors
22%
Kidney
22%
Preeclampsia
22%
Eculizumab
21%
Clinical Outcomes
19%
Rare Genetic Variants
17%
Complement Proteins
17%
Variants of Uncertain Significance
16%
Autoimmune Disease
15%
Kidney Transplant
15%
Renal Disease
14%
Genetic Testing
13%
Rare Variants
13%
Complement Dysregulation
13%
Alternative Pathway
12%
Functional Analysis
12%
Terminal Pathway
12%
Pregnancy Disorders
12%
Etiology
11%
Complement Cascade
11%
Pathophysiology
11%
Missense Variants
11%
Kidney Transplant Recipients
10%
Dysregulated
10%
Disease-associated
10%
Renal Transplant
10%
Genetic Etiology
10%
National Kidney Foundation
10%
Kidney Disease
10%
Complement Regulators
9%
Functional Assay
9%
Complement Pathway
9%
Genetic Progression
8%
Early Onset Drusen
8%
Idiopathic Membranous Nephropathy
8%
CD46
8%
COVID-19
8%
Perioperative Evaluation
8%
Medicine and Dentistry
Thrombotic Thrombocytopenic Purpura
93%
Atypical Hemolytic Uremic Syndrome
82%
Diseases
46%
Complement System
42%
Kidney Graft
38%
Complement Activation
33%
Kidney Transplantation
27%
Glomerulopathy
26%
Microangiopathy
21%
Eculizumab
20%
Complement Factor I
17%
Nephropathy
17%
Age Related Macular Degeneration
15%
Pre-Eclampsia
14%
Autoimmune Disease
13%
Pathophysiology
12%
Membrane Cofactor Protein
11%
Genetic Screening
11%
Complement Factor H
11%
Genetic Disorder
9%
Complement Component C3
9%
End Stage Renal Disease
9%
Elevated Transaminases
8%
Low Platelet Count
8%
Quality of Life
8%
Ravulizumab
8%
Puerperium
8%
COVID-19
8%
Complement Regulator
8%
Membranous Glomerulonephritis
8%
Cytomegalovirus
8%
Membranoproliferative Glomerulonephritis
8%
Nephrology
8%
Population Health
8%
Chronic Kidney Disease
8%
Autoantibodies
8%
Disease
8%
Systemic Lupus Erythematosus
7%
Recurrent Disease
7%
Genetic Variability
7%
Thrombosis
7%
Complement Inhibitor
7%
Anticomplement
6%
Antigen Antibody Complex
6%
End Organ Damage
6%
Thrombocytopenia
6%
Allograft
6%
Infection
6%
Kidney Disorder
5%
Public Health
5%